FRIST THOMAS F III
FRIST THOMAS F III's purchase track record
FRIST THOMAS F III has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/3/2022 | VRSN | $21K | -17.6% | -16.6% | -9.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
VeriSign Stock Considered Expensive Despite Monopoly. A recent analysis notes that VeriSign’s share price is high relative to its earnings and peers, even though the company holds a dominant position in domain name registration. The stock trades near the top of its 52‑week range and sits above a key support level at $292.94. With a trailing P/E of 32.5 and a modest dividend yield of 1.10%, the valuation is a point of discussion for investors.
Transaction History
| HCA | ▲ Buy | Grant | 1,041 | $0 | 4/28/2026 | View on chart |
| HCA | ▼ Sell | Other | 36,629,188 | — | 2/6/2026 | View on chart |
| HCA | ▼ Sell | Other | 36,557,141 | — | 2/6/2026 | View on chart |
| HCA | ▲ Buy | Grant | 1,320 | $0 | 4/29/2025 | View on chart |
| VRSN | ▲ Buy | Grant | 1,408 | $0 | 7/22/2024 | View on chart |
| HCA | ▲ Buy | Grant | 1,284 | $0 | 4/29/2024 | View on chart |
| VRSN | ▲ Buy | Grant | 1,179 | $0 | 7/24/2023 | View on chart |
| HCA | ▲ Buy | Grant | 1,396 | $0 | 4/24/2023 | View on chart |
| VRSN | ▲ Buy | Grant | 1,377 | $0 | 7/25/2022 | View on chart |
| HCA | ▲ Buy | Grant | 1,899 | $0 | 4/25/2022 | View on chart |
| VRSN | ▲ Buy | Open Market | 95 | $21K | 3/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
HCA Q2 Earnings and Analyst Optimism Amid Valuation Concerns
HCA Healthcare reported strong Q2 earnings compared to other hospital chains, prompting TD Cowen to raise its price target to $460. While some analysts note the stock could trade at a discount following a 96% run, others argue its strong outpatient partnerships and financial health make it too healthy to downgrade. The company's solid performance continues to draw attention from major market lists and value stock screens.
HCA Q2 Earnings and Analyst Optimism Amid Valuation Concerns. HCA Healthcare reported strong Q2 earnings compared to other hospital chains, prompting TD Cowen to raise its price target to $460. While some analysts note the stock could trade at a discount following a 96% run, others argue its strong outpatient partnerships and financial health make it too healthy to downgrade. The company's solid performance continues to draw attention from major market lists and value stock screens.